<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/190BD952-CE26-4CA2-BA05-BB86BDE8F499"><gtr:id>190BD952-CE26-4CA2-BA05-BB86BDE8F499</gtr:id><gtr:name>Cell Medica Limited</gtr:name><gtr:address><gtr:line1>1 CANAL SIDE STUDIOS , 8-14 ST PANCRAS WAY</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1 0QG</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/190BD952-CE26-4CA2-BA05-BB86BDE8F499" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>190BD952-CE26-4CA2-BA05-BB86BDE8F499</gtr:id><gtr:name>Cell Medica Limited</gtr:name><gtr:address><gtr:line1>1 CANAL SIDE STUDIOS , 8-14 ST PANCRAS WAY</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1 0QG</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>749908.0</gtr:offerGrant><gtr:projectCost>1249847.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/091DC813-9069-4666-8998-1D89E081C9F2" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>091DC813-9069-4666-8998-1D89E081C9F2</gtr:id><gtr:name>Cell Therapy Catapult Limited</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1249744.0</gtr:offerGrant><gtr:projectCost>1249744.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=103237"><gtr:id>8FB9509E-6F2E-46D0-B91D-F4312C91E57F</gtr:id><gtr:title>Project SILKIN</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>103237</gtr:grantReference><gtr:abstractText>Cell Medica develops novel cellular immunotherapy products for treating cancer. These therapies rely on harnessing the human immune system to treat cancer and represent a significant advance over traditional chemotherapy because the immune cells are activated to attack the malignant cells and not the healthy cells of the body. This project is a collaboration between Cell Medica, a company founded in the UK in 2007, and the Cell and Gene Therapy Catapult (CGTC). It will support increased knowledge about the functionality of these products and how to manufacture them at an acceptable cost to ensure widespread availability within the UK healthcare system. The teams will also work on ways to measure how the cells act to kill cancer cells which will then inform us how to manufacture these products for maximal patient specific benefit. We will be working closely with regulatory bodies to understand requirements to supply multiple different products in parallel from the same facility, thereby reducing further reducing costs. The experience with this project will allow the training of two ?Qualified Persons' who will become experts in the approval of products for use in humans.</gtr:abstractText><gtr:fund><gtr:end>2020-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1999652</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">103237</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>